Alzchem Group AG Conversion to registered shares with a new ISIN DE000A41YHG1 is proceeding as planned – temporary discrepancies in portfolio displays are possible

Alzchem Group AG: Conversion to registered shares with a new ISIN DE000A41YHG1 is proceeding as planned – temporary discrepancies in portfolio displays are possible

Trostberg, September 18, 2026 – Alzchem Group AG, a globally active specialty chemicals company, is currently implementing the conversion from bearer shares to registered shares, as resolved by the Annual General Meeting on May 5, 2026. The associated technical processes are proceeding as planned. In particular, the shares can already be traded under the new ISIN. However, the adjustment of individual shareholders’ securities account balances will occur on a staggered basis; it is expected to be completed by September 21, 2026.

During this phase, individual securities accounts may temporarily still display the previous (bearer) share position or even a value of EUR 0. These discrepancies in the securities account display, however, have no impact on the number of shares held by shareholders or the associated rights. The right to sell the shares is also not restricted by the change. In the event of any discrepancies, shareholders should contact their custodian bank immediately.

About Alzchem

Alzchem is an internationally leading ingredients company that provides sustainable solutions for global challenges such as climate change, population growth, defense, and rising life expectancy with highly functional specialty products. Its portfolio includes products that are highly relevant to its customers’ end uses. Alzchem is positioned as the global market leader in numerous niche markets. The ingredients produced by Alzchem are used in human and animal nutrition as well as in agriculture, among other areas. They thus make an important contribution to efficiently securing the global food supply. Pharmaceutical raw materials and high-quality creatine products also support healthy aging and modern health concepts. In addition, Alzchem is active in the fields of renewable energies and customer-specific specialty syntheses, as well as with essential high-performance products for safety-related applications. Consistent “Made in Germany” production stands for the highest quality, technological expertise, and reliable supply security.

With over 1,700 employees at four locations in Germany, one plant in Sweden, and three sales companies in the USA, China, and England, Alzchem generated sales of EUR 562.1 million and EBITDA of EUR 116.5 million in 2025.